External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

(Updates with fund discount in third paragraph.)

(Bloomberg) -- BB Biotech AG jumped the most in more than two years after activist investor Paul Singer increased his stake in the fund, the best-performing health-care portfolio in the world last year.

Singer, who runs hedge-fund firm Elliott Management, raised his stake in the Kuesnacht, Switzerland-based company to 5.47 percent as of Dec. 23 from 3.11 percent previously, according to a filing with Swiss Six Exchange.

The investment may be a prelude to a campaign by Singer to close the 19 percent discount between BB Biotech’s share price and the value of the investments it owns. The fund in the past has bought back shares to reduce the discount to less than 15 percent. Elliott and BB Biotech declined to comment when asked about the rationale behind Singer’s investment.

“My guess is that Elliott will press the company for a share buyback or something else to address the persistent discount,” Phil Goldstein, a principal at activist fund Bulldog Investors, said by phone today. “Based on past experience I’d say some action by Elliott is likely.”

BB Biotech rose 3.2 percent to 251.75 Swiss francs at 5:10 p.m. in Zurich after gaining as much as 7.2 percent, the biggest intraday advance since July 2012.

The fund, whose management team is headed by Daniel Koller, returned 75 percent last year, the best performance of any health-care fund in the world, according to data compiled by Bloomberg. BB Biotech’s largest holdings as of Sept. 30 included Celgene Corp., Gilead Sciences Inc. and Actelion Ltd.

Singer and BB Biotech have crossed paths before. The hedge fund manager is best-known in Switzerland for his attempt to replace Actelion’s board and seek a buyer for that company in 2011. Back then BB Biotech supported Actelion to fight off Elliott’s approach.

Regardless of Singer’s intentions, his purchase of shares is encouraging investors.

“The increase is a positive signal to the market,” said Navid Malik, an analyst at Cenkos Securities. He has a buy recommendation on BB Biotech. “We expect a spectacular year for small and midcap biotechs, and BB Biotech will have exposure to this.”

BB Biotech has gained about nine-fold since Switzerland’s Bank am Bellevue listed the biotechnology fund on the stock exchange in 1993.

--With assistance from Katherine Burton in New York.

To contact the reporter on this story: Jan-Henrik Förster in Zurich at jforster20@bloomberg.net To contact the editors responsible for this story: Mariajose Vera at mvera1@bloomberg.net Phil Serafino, Kim McLaughlin

Bloomberg